Nonetheless, these response rates coupled with significant improvements in other effectiveness (MMD/MHD with peak VAS pain ≥ 5, MAIs) and disability measures (MIDAS and HIT-6 scores), point altogether at quite significant remissions in migraine monthly frequency, mostly pronounced in HFEM patients after the second eptinezumab infusion (T2), rather than in the first (T1).
← all excerpts
Eptinezumab to prevent difficult-to-treat migraine: prospective, six-month, real-world multicenter evidence from the GRASP study group.
1
—
—